Legend Biotech's Cilta-cel Approved in China for Multiple Myeloma
Ticker: LEGN · Form: 6-K · Filed: Aug 27, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, china, oncology, car-t
Related Tickers: LEGN
TL;DR
China NMPA approves Legend Biotech's cilta-cel for multiple myeloma!
AI Summary
On August 27, 2024, Legend Biotech Corporation announced that China's National Medical Products Administration (NMPA) approved their New Drug Application for ciltacabtagene autoleucel (cilta-cel). This approval is for adult patients in China with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy.
Why It Matters
This NMPA approval marks a significant market expansion for Legend Biotech's CAR-T therapy, potentially improving treatment options for a large patient population in China.
Risk Assessment
Risk Level: medium — Regulatory approvals are positive, but market adoption, competition, and manufacturing scale-up present ongoing risks.
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- Ciltacabtagene autoleucel (drug) — Approved therapy
- cilta-cel (drug) — Abbreviated therapy name
- China (country) — Approval jurisdiction
- National Medical Products Administration (NMPA) (company) — Regulatory body
- August 27, 2024 (date) — Approval date
- Multiple Myeloma (disease) — Treated condition
FAQ
What specific patient population in China is eligible for cilta-cel treatment?
Adult patients with relapsed or refractory multiple myeloma who have disease progression after receiving at least three prior lines of therapy.
Which regulatory body in China granted the approval for cilta-cel?
China's National Medical Products Administration (NMPA).
What is the full name of the drug approved by the NMPA?
Ciltacabtagene autoleucel.
On what date was the NMPA approval announced?
August 27, 2024.
What is the ticker symbol for Legend Biotech Corporation?
The filing does not explicitly state the ticker symbol, but it is commonly known as 'LEGN'.
Filing Stats: 285 words · 1 min read · ~1 pages · Grade level 15.8 · Accepted 2024-08-27 07:30:05
Filing Documents
- f6k_082724.htm (6-K) — 10KB
- 0001171843-24-004939.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: August 27, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer